ongoing

5.3.9. Crizotinib – XALKORI (CAP) - EMEA/H/C/002489/II/0039
Applicant: Pfizer Limited
PRAC Rapporteur: Isabelle Robine
Scope: Extension of indication to include the treatment of adults with ROS1-positive
advanced non-small cell lung cancer (NSCLC) based on the results of study A8081001 (a
multinational, multicentre, open-label, single-arm study of the safety, pharmacokinetics,
pharmacodynamics, and antitumor activity of crizotinib in patients with advanced cancer).
Consequential changes are proposed to SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 and
the Package Leaflet and RMP (version 7.0) are updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.10. Dolutegravir – TIVICAY (CAP) - EMEA/H/C/002753/X/0018/G
Applicant: ViiV Healthcare UK Limited
PRAC Rapporteur: Julie Williams
Scope: Extension application to add two new strengths (10 mg and 25 mg tablets) to
support the extension of the indication for the treatment of paediatric patients from 6 years
of age infected with human immunodeficiency virus (HIV). Data from cohort I and II A of
the clinical trial ING112578 are presented in support of the new therapeutic indication
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.11. Eltrombopag, eltrombopag olamine – REVOLADE (CAP) -
EMEA/H/C/001110/II/0029/G
Applicant: Novartis Europharm Ltd
PRAC Rapporteur: Dolores Montero Corominas
Scope: Update of sections 4.4 and 4.8 of the SmPC with reference to bone marrow reticulin
formation and risk of bone marrow fibrosis and section 5.1 of the SmPC with updated
exposure data, based on the final study reports for study TRA112940 (a longitudinal 2-year
bone marrow study of eltrombopag olamine (SB-497115-GR) in previously treated adults,
with chronic immune (idiopathic) thrombocytopenic purpura (ITP)) and study TRA105325
(EXTEND (Eltrombopag eXTENded Dosing study) an extension study of eltrombopag olamine
(SB-497115-GR) in adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP)
previously enrolled in an eltrombopag study). As a consequence, Annex II is updated in
order to delete ‘increased bone marrow reticulin fibres’ from the key elements to be
included in the educational material. In addition, the MAH took the opportunity to propose
an update of the due date in the RMP for the provision of the final clinical study report
(CSR) for MEA 022.1 (effectiveness of educational materials for hepatitis C associated
thrombocytopenia). The RMP (version 36) is updated accordingly
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.12. Empagliflozin, metformin – SYNJARDY (CAP) - EMEA/H/C/003770/II/0015
Applicant: Boehringer Ingelheim GmbH
PRAC Rapporteur: Miguel-Angel Macia
Scope: Extension of indication to include the treatment with Synjardy as adjunct to
standard care therapy in adult patients with type 2 diabetes mellitus and high
cardiovascular risk when the treatment with empagliflozin and metformin is appropriate and
empagliflozin is needed to reduce the risk of all-cause mortality by reducing cardiovascular
death and cardiovascular death or hospitalization for heart failure. As a consequence,
sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated based on the final clinical study
Pharmacovigilance Risk Assessment Committee (PRAC)
EMA/PRAC/325452/2016 Page 21/52